Synthon’s generic versions of Zeposia infringe US Patent No. 11,680,050, which covers specific crystalline forms of the drug’s active ingredient, ozanimod hydrochloride, and a method for preparing them, Bristol-Myers and its Receptos LLC unit said in a complaint filed Tuesday in the US District Court for the District of Delaware.
Synthon didn’t immediately respond to a request for comment.
- The patent expires in September 2038, according to the US ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.